NCT06479187View on ClinicalTrials.gov

PSMAtrack-tracking Changes in PSMA-PET During Initial Therapy for Metastatic Hormone-sensitive Prostate Cancer

PHASE4RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

June 30, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

June 20, 2027

Conditions
Metastatic Prostate CancerHormone Sensitive Prostate CancerMetastatic Hormone-sensitive Prostate Cancer (mHSPC)
Interventions
DRUG

18F-rhPSMA-7.3

radiopharmaceutical targeting PSMA and used to image prostate cancer with PET scan.

DEVICE

PET/CT

Diagnostic imaging test

Trial Locations (2)

02115

RECRUITING

Dana Farber Cancer Institute, Boston

02215

RECRUITING

Dana-Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

Blue Earth Diagnostics
All Listed Sponsors
collaborator

Dana-Farber Cancer Institute

OTHER

collaborator

Blue Earth Diagnostics

INDUSTRY

lead

Brigham and Women's Hospital

OTHER